Dear Doctor Letters regarding citalopram and escitalopram: guidelines vs real-world data
Sign Up to like & getrecommendations! Published in 2022 at "European Archives of Psychiatry and Clinical Neuroscience"
DOI: 10.1007/s00406-022-01392-x
Abstract: Dear Doctor Letters (DDLs, Direct Healthcare Professional Communications) from 2011 provided guidance regarding QTc-prolonging effects with risk of torsade de pointes during treatment with citalopram and escitalopram. This study examines the DDLs’ effects on prescription… read more here.
Keywords: dear doctor; citalopram escitalopram; doctor letters; escitalopram ... See more keywords
Use of QTc-prolonging medications among patients with lung cancer: implications for clinical trials and standard clinical care.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e20529
Abstract: e20529Background: Exclusion from cancer clinical trials is common for patients taking QTc-interval prolonging drugs. To estimate the potential impact on accrual, we determined the prevalence of QTc... read more here.
Keywords: prolonging medications; clinical trials; cancer; qtc prolonging ... See more keywords